Optimal Biological Dose Combination Finding: A Design Roadmap and Robust Cross-Indication Bayesian Borrowing
Early-phase combination oncology trials increasingly seek the optimal biological dose combination (OBDC) rather than a maximum tolerated dose combination, in line with the FDA's Project Optimus initiative. Existing Bayesian OBDC designs span rule-based, model-assisted, and model-based paradigms, but no unified framewor...